ViewRay Announces Conference Call for Second Quarter 2020 Financial Results to be Held After Market on July 30, 2020

Rhea-AI Summary

ViewRay, Inc. (Nasdaq: VRAY) scheduled a conference call for July 30, 2020, to discuss its second quarter 2020 financial results. The call will begin at 4:30 p.m. ET and will be accessible via dial-in and live webcast. ViewRay's MRIdian® MR-Guided Radiation Therapy System is highlighted as a key product. The company warns of risks related to the COVID-19 pandemic, its ability to convert backlog into revenue, and the uncertainty surrounding clinical trials. Further information can be found on the investor relations page of the company's website.

Positive

• None.

Negative

• Risks related to COVID-19 impacting demand and operations.
• Uncertainty in converting backlog into revenue.
• Risks associated with clinical trials and product development.

CLEVELAND, July 13, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2020 financial results.

ViewRay will hold a conference call to discuss results on Thursday, July 30, 2020 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 4968496. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at www.investors.viewray.com.

After the live webcast, a replay will remain available online on the investor relations page of ViewRay's corporate website, www.investors.viewray.com, for 14 days following the call. In addition, a telephonic replay of the call will be available until August 6, 2020. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number 4968496.

About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the rate of new orders, upgrades, and installations, ViewRay's preliminary second quarter results and anticipated future operating and financial performance, and ViewRay's conference call to discuss its second quarter 2020 results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the recent COVID-19 (coronavirus) pandemic, including its impacts across our businesses on demand, operations and our global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and its Quarterly Reports on Form 10-Q, as updated periodically with the company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/viewray-announces-conference-call-for-second-quarter-2020-financial-results-to-be-held-after-market-on-july-30-2020-301092012.html

SOURCE ViewRay, Inc.

FAQ

When is ViewRay's conference call for Q2 2020 financial results?

The conference call is scheduled for July 30, 2020, at 4:30 p.m. ET.

Where can I access the conference call for ViewRay's financial results?

The conference call can be accessed via dial-in numbers or live webcast on ViewRay's investor relations page.

What products does ViewRay focus on?

ViewRay focuses on the MRIdian® MR-Guided Radiation Therapy System.

What risks does ViewRay highlight in its press release?

ViewRay highlights risks related to COVID-19, clinical trial uncertainties, and backlog revenue conversion.